What is a sponsor-investigator in clinical trials?

Most clinical trials involve two separate parties. A sponsor, usually a pharmaceutical or biotechnology company, initiates and funds the study. An investigator, usually a physician at a hospital or research center, conducts the study with participants. These roles stay distinct so that oversight and day-to-day conduct do not sit with the same person.

A sponsor-investigator is different. In this arrangement, one individual takes on both roles at once. The same person who designs and files the trial with regulators also runs the study procedures with participants at the site. The United States Food and Drug Administration (FDA) defines this role in federal regulation, and it appears in a meaningful share of trials that participants encounter today, particularly at academic medical centers.

This article explains what the sponsor-investigator role means, why the arrangement exists, and what participants should understand about oversight and safety when the same person runs and funds the trial.

What a sponsor-investigator actually is

The FDA defines a sponsor-investigator as an individual who both initiates and conducts a clinical investigation, and under whose immediate direction the study drug is administered or dispensed. The regulation is specific: the role can only be held by a single person, not a company or an institution. That person carries the legal obligations of a sponsor and the clinical duties of an investigator simultaneously.

To understand what this means, it helps to separate the two functions.

A sponsor is responsible for the regulatory side of a clinical trial. This includes filing the paperwork that allows the trial to begin, maintaining records with the FDA, reporting safety issues, and overseeing how the study is monitored. In most trials, this work is done by a company with a team of regulatory professionals.

An investigator is the physician who runs the study at the site. This person recruits participants, obtains informed consent (the formal process where a participant learns about the study and agrees to join), delivers the study procedures, and reports adverse events.

When a single physician takes on both jobs, the trial is called a sponsor-investigator study, or more informally an investigator-initiated trial. A participant-focused overview of clinical research basics covers the roles and structure of a trial in more detail.

Why one person sometimes runs and funds a trial

Sponsor-investigator trials exist to fill gaps in medical research. Pharmaceutical companies focus on studies that support products they plan to bring to market. That leaves many important medical questions without a commercial funder. Physician-scientists and academic researchers step in to answer those questions themselves.

The arrangement is common in several situations.

Rare disease research often depends on sponsor-investigator trials. When a condition affects only a small population, the commercial return on developing a new therapy is limited, so companies may not pursue it. A researcher who studies the condition can initiate a trial through their academic institution and obtain funding from foundations, patient advocacy groups, or government agencies.

Repurposed drug studies also fit this model. When an existing generic medicine shows promise for a new use, no company typically has an incentive to fund the pivotal study because there is no exclusive product to sell. An investigator can pursue that research independently.

Pediatric studies, head-to-head comparisons of existing therapies, and studies of novel scientific hypotheses that emerge from a researcher's own laboratory also frequently take the sponsor-investigator route. Together, these categories represent a substantial share of the clinical research participants encounter, especially at university medical centers. Rare disease research is one of the most active areas for investigator-led trials.

The dual responsibilities behind the role

Holding both roles means doing two demanding jobs at once. This is not a technicality. It shapes how the trial is set up and how oversight functions in practice.

On the sponsor side, the individual must file an Investigational New Drug application (IND) with the FDA before enrolling any participant. The IND includes the trial plan, the proposed informed consent document, and available safety data from earlier studies. The FDA has a thirty-day review window in which it can raise concerns or halt the trial before it begins. Once approved, the sponsor-investigator files annual progress reports, submits any changes to the trial for review, and reports serious safety events on strict timelines set by federal rules.

On the investigator side, the same person is responsible for obtaining informed consent from each participant, following the approved trial plan, protecting participant welfare at the site, and reporting adverse events accurately.

Carrying both loads is genuinely difficult. Most sponsor-investigators rely on their institution's research administration office, regulatory affairs staff, and clinical trial support units to handle much of the sponsor-side workload. This institutional support is one reason sponsor-investigator trials are concentrated at academic medical centers, which have the infrastructure to support the arrangement. Institutional infrastructure plays a significant role in how clinical trials advance medicine.

How participant safety is protected in these trials

A reasonable question for any participant considering a sponsor-investigator trial is whether the same protections apply as in company-run studies. The answer is that oversight in clinical research is deliberately layered and independent, and those layers apply regardless of who runs or funds the trial.

The first layer is the Institutional Review Board, often called an IRB. An IRB is an independent ethics committee that must review and approve a trial before it begins and continue to monitor it over time. Its role is to protect the rights, safety, and welfare of participants. Federal rules require IRB members with a conflicting interest to step aside from reviewing that particular trial. The IRB is structurally separate from the researcher running the study, whether that researcher is an academic physician or works for a company.

The second layer is the FDA itself. The agency reviews the initial trial application, can pause a trial through a formal hold, and conducts on-site inspections of both sponsors and investigators. A specific FDA inspection program exists for clinical investigators and sponsor-investigators.

The third layer, used in higher-risk studies, is a Data Safety Monitoring Board (DSMB). This is an independent panel of outside experts, free of ties to the research team, that periodically reviews accumulating safety data and can recommend modifying or stopping a trial. The National Institutes of Health require DSMBs for all multi-site trials involving significant risk.

A fourth safeguard is financial disclosure. When a researcher has a financial or personal interest in the outcome of a trial, that interest must be disclosed to the institution and the IRB. The IRB can require the interest to be disclosed to participants in the consent form, or can require independent oversight of the trial to manage the conflict. Federal guidance specifically flags the situation where the investigator is also the participant's regular treating physician. In that case, the consent process must make clear that joining is entirely voluntary and that declining will not affect the person's ongoing medical care. Understanding these protections helps clear up common misconceptions about clinical research.

How to tell if a trial is investigator-led

Participants can often identify a sponsor-investigator trial by looking at how it is registered on ClinicalTrials.gov, the public database of clinical trials in the United States. Each listing has a Sponsor field and a Collaborators field.

In a company-sponsored trial, the sponsor field lists the pharmaceutical or biotechnology company that owns the product. In a sponsor-investigator or investigator-initiated trial, the sponsor field typically lists a university, medical center, or the individual researcher. Foundations, government agencies, or industry partners who provide funding often appear as collaborators rather than as the sponsor.

The informed consent document is another place to look. Federal rules require the consent document to describe how the trial is funded and to disclose any significant financial interest the researcher has in the outcome, along with how that interest is being managed. A well-run trial will explain this clearly rather than burying it in dense language. A step-by-step approach can help make finding and evaluating a trial easier.

Questions worth asking the study team

Whether a trial is company-sponsored or investigator-led, participants have the right to ask about how it is set up. A short list of practical questions can clarify the arrangement.

• Who is the sponsor of this trial, and who is providing the funding?
• Does the physician running the trial have a financial interest in the study drug, device, or outcome, and how is that interest managed?
• Which Institutional Review Board reviewed and approved this study?
• Is there a Data Safety Monitoring Board or an independent safety monitor?
• If the study doctor is also the participant's regular treating physician, what happens to ongoing care if the participant declines to join or decides to leave the study?

Study teams are accustomed to these questions and should be able to answer them plainly. A team that struggles to answer, or that responds vaguely, is worth pausing over. A more complete question checklist can help prepare for the conversation with a study team.

How DecenTrialz supports participants exploring clinical trials

Finding a trial that matches a participant's condition, location, and personal preferences is one of the earliest and most confusing parts of the clinical trial journey. Sponsor-investigator trials add to that complexity because they may be listed under a university or medical center rather than a recognizable company name.

DecenTrialz is a clinical trial recruitment platform designed to make this stage easier. Participants share information about their health and preferences, an AI-assisted matching system identifies trials that align with their profile, and a registered nurse conducts an initial pre-screening review. From there, the study team at the research site takes over: they walk the participant through eligibility, informed consent, and enrollment. Whether the trial is run by a large company or by an individual sponsor-investigator at an academic center, the same matching and pre-screening approach helps participants explore their options with clearer information. To see how the process works or explore active trials, visit decentrialz.com.

Making an informed decision about joining a trial

The sponsor-investigator arrangement is a legitimate and often valuable structure in clinical research. It fills gaps that industry does not address and supports important work in rare diseases, pediatric medicine, drug repurposing, and academic science. The safeguards that protect participants in company-sponsored trials, including independent ethics review, FDA oversight, financial disclosure, and data safety monitoring, apply equally to sponsor-investigator studies.

Being an informed participant does not mean being suspicious of researchers. It means knowing what to ask, understanding what the answers mean, and recognizing that layered oversight exists to protect the people who volunteer for research. That awareness is worth carrying into any conversation with a study team.

Participants interested in learning more about active clinical trials or beginning a pre-screening conversation can start at decentrialz.com.